Thursday, June 30, 2022
    HomeHealthBiotech startup looks to sidestep key problem with CAR-T cancer therapies

    Biotech startup looks to sidestep key problem with CAR-T cancer therapies


    Tlisted here are two issues Phil Greenberg, the pinnacle of immunology at Fred Hutchinson Most cancers Analysis Heart, is very well-known for: a attribute wiry grey mop of hair and large glasses, and a rock-solid status as one of many main researchers in most cancers immunotherapy.

    Greenberg was behind a few of the key scientific advances that led to breakthrough CAR-T cell therapies, and co-founded Juno Therapeutics, a biotech that helped launch one of many first of these remedies. Now, he’s co-founding a brand new enterprise referred to as Affini-T Therapeutics, a Seattle and Massachusetts-based firm that hopes to get rid of cancers by focusing on the supply of most cancers cells. The budding biotech, unveiled this week on the JPM Well being Care Convention, will use a comparatively new know-how generally known as engineered T-cell receptors, or TCRs, to focus on oncogenic driver mutations, errors in key genes that trigger cells to revolt and switch malignant within the first place.

    Unlock this text by subscribing to STAT+ and revel in your first 30 days free!


    Source link

    Related articles

    Stay Connected


    Latest posts